Innoviva Management

Management criteria checks 4/4

Innoviva's CEO is Pavel Raifeld, appointed in May 2020, has a tenure of 4.67 years. total yearly compensation is $868.65K, comprised of 55.8% salary and 44.2% bonuses, including company stock and options. directly owns 0.019% of the company’s shares, worth $202.45K. The average tenure of the management team and the board of directors is 3 years and 6.9 years respectively.

Key information

Pavel Raifeld

Chief executive officer

US$868.6k

Total compensation

CEO salary percentage55.8%
CEO tenure4.7yrs
CEO ownership0.02%
Management average tenure3yrs
Board average tenure6.9yrs

Recent management updates

Recent updates

Innoviva, Inc.'s (NASDAQ:INVA) Popularity With Investors Is Under Threat From Overpricing

Dec 19
Innoviva, Inc.'s (NASDAQ:INVA) Popularity With Investors Is Under Threat From Overpricing

Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price

Jul 26
Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price

Innoviva: Potentially Overvalued

Jun 21

Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

May 21
Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly

Feb 05
Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Nov 04
Is Innoviva (NASDAQ:INVA) A Risky Investment?

Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly

Mar 02
Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly

Innoviva Stock? Not Yet. Short Puts? Definitely.

Sep 19

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Sep 19
Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Jun 16
Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Continuing To Avoid Innoviva Inc.

Jun 07

We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease

Mar 04
We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease

Taking Innoviva Winnings Off The Table, Again

Feb 21

Innoviva Inc.: Short Puts Are Compelling

Jan 15

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Oct 19
Is Innoviva (NASDAQ:INVA) A Risky Investment?

Taking Profits In Innoviva Inc.

Oct 16

Innoviva reports Q1 results

Apr 28

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Mar 30
These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Mar 04
Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

Jan 15
Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Dec 25
These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?

Dec 04
Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?

Innoviva: Only For Short-Term Traders

Nov 04

Innoviva reports Q3 results

Oct 28

CEO Compensation Analysis

How has Pavel Raifeld's remuneration changed compared to Innoviva's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$65m

Jun 30 2024n/an/a

US$145m

Mar 31 2024n/an/a

US$181m

Dec 31 2023US$869kUS$485k

US$180m

Sep 30 2023n/an/a

US$50m

Jun 30 2023n/an/a

US$233m

Mar 31 2023n/an/a

US$233m

Dec 31 2022US$2mUS$440k

US$214m

Sep 30 2022n/an/a

US$293m

Jun 30 2022n/an/a

US$99m

Mar 31 2022n/an/a

US$188m

Dec 31 2021US$1mUS$391k

US$266m

Sep 30 2021n/an/a

US$309m

Jun 30 2021n/an/a

US$265m

Mar 31 2021n/an/a

US$253m

Dec 31 2020US$2mUS$222k

US$224m

Compensation vs Market: Pavel's total compensation ($USD868.65K) is below average for companies of similar size in the US market ($USD3.24M).

Compensation vs Earnings: Pavel's compensation has been consistent with company performance over the past year.


CEO

Pavel Raifeld (40 yo)

4.7yrs

Tenure

US$868,648

Compensation

Mr. Pavel Raifeld, CFA, is Director of La Jolla Pharmaceutical Company since August 22, 2022. He serves as Chief Executive Officer of Innoviva, Inc. since May 2020. He is a seasoned healthcare executive wi...


Leadership Team

NamePositionTenureCompensationOwnership
Pavel Raifeld
Chief Executive Officer4.7yrsUS$868.65k0.019%
$ 202.5k
Stephen Basso
Chief Financial Officer1.4yrsUS$1.18mno data
Marianne Zhen
Chief Accounting Officer & Secretary6.5yrsUS$924.21k0.072%
$ 779.7k
Patricia Drake
Chief Commercial Officer-Innoviva Specialty Therapeuticsless than a yearno datano data

3.0yrs

Average Tenure

56.5yo

Average Age

Experienced Management: INVA's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jules Haimovitz
Independent Director6.9yrsUS$446.02k0.19%
$ 2.0m
Sapna Srivastava
Independent Director2yrsUS$547.11k0.041%
$ 441.7k
Derek Small
Independent Directorless than a yearno datano data
Odysseas Kostas
Independent Director7.1yrsUS$331.18k0.17%
$ 1.9m
Sarah Schlesinger
Independent Director6.9yrsUS$367.25k0.17%
$ 1.8m
Mark DiPaolo
Independent Director6.9yrsUS$396.59k0.17%
$ 1.8m

6.9yrs

Average Tenure

53yo

Average Age

Experienced Board: INVA's board of directors are considered experienced (6.9 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 22:52
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Innoviva, Inc. is covered by 17 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jon LangenfeldBaird
James BirchenoughBarclays
Patrick TrucchioBerenberg